– USA, NY – Kallyope, Inc., a clinical-stage biotechnology company discovering and developing novel, oral small-molecule therapeutics for diseases with high unmet needs, today announced the appointment of Dr. Franz Humer (Ph.D.) to its Board of Directors as Chair, bringing decades of managerial experience to the Kallyope board.
“Dr. Humer is an accomplished global business leader with extensive strategic and operational experience and an unprecedented track record of success in the biopharmaceutical industry. It is an honor to welcome him to Kallyope as chair of our board of directors. Dr. Humer uniquely complements our already distinguished board of directors, at a significant time for our company. As we continue to advance our novel therapeutics in obesity and diabetes, gastrointestinal disease, and neurological disorders – and build our scientific and business operations – we will benefit from his tremendous knowledge and expertise,” said CEO, Jay Galeota.
About Dr. Franz Humer
Dr. Franz Humer served for over fifteen years as CEO and then chairman of Roche. Under his leadership, Roche rose to become one of the top three global pharmaceutical companies. He has served as chair of several international companies and currently serves as:
- Member of the board of directors, Allogene Therapeutics
- Chairman, HMNC Holding
- Member of the board of directors, Emil Frey Holdings
- Member of the board of directors, LetterOne
- Advisor, Breakthrough Properties (USA)
- Chairman, Humer Foundation
Following a career as a management consultant in Zurich, he joined Schering Plough Inc. in 1973, where he held several positions including GM for several countries in South America and Europe. He joined Glaxo Holdings in 1981 and was appointed MD of Glaxo Pharmaceuticals UK Ltd. in 1987. In 1989 he was elected to the Board of Glaxo Holdings plc, and in 1992, he became COO for Glaxo’s worldwide (ex-US) operations. Dr. Humer joined Hoffmann-La Roche in 1995 as head of its pharmaceuticals division and board member. He was appointed COO in 1996, CEO in 1998, and chairman of the board of directors and CEO in 2001. From 2008 to 2014 he served as chairman of the board of directors of Roche Holding Ltd.
He has also been chairman of Diageo plc, Citigroup New York, INSEAD, and the International Center of Missing and Exploited Children. He was a member of the board of Allianz SE, Jacobs Holding AG, Kite Pharmaceuticals, Temasek, Cydar Medical, and Neogene Therapeutics.
“I am privileged to join the Kallyope board of directors as chair at this exciting time for the company,” said Dr. Franz Humer. “The caliber of the Kallyope team, with their deep experience in drug discovery and development, track record of prior successes, and scientific accomplishment at the company to date, has created unique and important opportunities. I look forward to working closely with them to build the company and advance their meaningful work, which has great promise to address important unmet needs in human health.”
Dr. Humer earned a Ph.D. in law from the University of Innsbruck and an MBA at INSEAD.
About Kallyope
Kallyope, a clinical-stage biotechnology company, is leveraging its proprietary Klarity therapeutic platform to discover and develop novel, oral small-molecule therapeutics in areas with high unmet medical needs, including diabetes and obesity, gastrointestinal disease, and neurological disorders.
Source: https://kallyope.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
